The short answer
Weekly incretin dosing is achieved by binding albumin reversibly. Monthly dosing requires a different mechanism: conjugating the active peptides to a monoclonal antibody, which persists far longer because it is recycled by the neonatal Fc receptor rather than merely shielded.
Key facts
- Weekly mechanism
- Reversible albumin binding
- Monthly mechanism
- Antibody conjugation
- Key receptor
- Neonatal Fc receptor (FcRn)
- Antibody persistence
- Weeks, not hours
- Example
- Maridebart cafraglutide, once monthly
- Phase 2 readout
- NEJM, 4 September 2025
What albumin binding achieves and where it stops
A fatty acid attached to a peptide binds albumin reversibly, which prevents renal filtration and shields against proteases. That takes native GLP-1 from minutes to about a week for semaglutide. It is a shielding strategy (the peptide survives longer because it is hidden), and roughly a week is where that approach plateaus.
Why antibodies last so much longer
Not shielding but active rescue. The neonatal Fc receptor binds antibodies taken up into cells and returns them to circulation instead of allowing degradation. That recycling is why monoclonal antibodies persist for weeks: they are not merely evading clearance, they are being retrieved from it.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
The conjugate idea
Attach the pharmacologically active peptides to an antibody and they inherit its pharmacokinetics. Maridebart cafraglutide does this: a monoclonal antibody against the GIP receptor, with GLP-1 receptor agonist peptides conjugated through amino-acid linkers. The antibody is not a passive carrier. It is itself one of the two pharmacological actions, but it also supplies the duration.
Why monthly dosing is worth engineering for
Adherence to any chronic treatment declines with how often it must be taken, and a self-administered weekly injection is a recurring demand. Twelve administrations a year rather than fifty-two is a different proposition, particularly for a condition requiring indefinite treatment. Whether that translates into better real-world outcomes is a separate question from whether it is pharmacologically achievable.
What long duration costs
Control. A compound with a one-week half-life is largely cleared within a month of stopping; one dosed monthly is not. If adverse effects appear, they cannot be ended promptly by withholding the next dose. Long duration is a convenience benefit and a reversibility cost, and the two are inseparable.
Regulatory position
Maridebart cafraglutide is investigational and holds no marketing authorisation anywhere. Its Phase 3 programme is ongoing. Nothing supplied here is related to it or to any licensed weight-management medicine.
Quick reference
| Strategy | Mechanism | Interval |
|---|---|---|
| Native GLP-1 | None | Minutes |
| C16 palmitic (liraglutide) | Weak albumin binding | Daily |
| C18/C20 diacid | Strong albumin binding | Weekly |
| Antibody conjugate | FcRn recycling | Monthly |
Frequently asked questions
Why can't albumin binding give monthly dosing?
It is a shielding strategy with a practical ceiling around a week. Antibodies persist longer because FcRn actively retrieves them from degradation.
What is the neonatal Fc receptor?
A receptor that binds antibodies taken into cells and returns them to circulation rather than letting them be degraded. It is the basis of antibody persistence.
What is the downside of monthly dosing?
Reversibility. A long-acting compound cannot be cleared quickly by withholding the next dose if adverse effects appear.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedJastreboff AM et al., Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity: A Phase 2 Trial. NEJM 2025 (PMID 40549887)pubmed.ncbi.nlm.nih.gov
- PubMedCoskun T et al., LY3437943 triple agonist. Cell Metab 2022 (PMID 35985340)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · Liraglutide (CID 16134956)pubchem.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- Blocking and Activating the Same Receptor, in One ModelTirzepatide activates GIPR; MariTide blocks it. Both work. A February 2026 mouse study finally compared the two directions under matched conditions.
- Why Population-Specific Trials Are RunOASIS 2 studied oral semaglutide in an East Asian population. Why obesity thresholds and drug response differ, and what a dedicated trial establishes.
- The Question Underneath the Lean Mass DebateAll weight loss costs fat-free mass, including diet and surgery. The real questions are whether incretins cost more, and whether it has functional consequences.
- What Fat-Free Mass Actually ContainsBone, organs, water and blood-forming tissue all sit inside the fat-free compartment. Treating the number as a muscle measurement is a category error.
- The Method Determines the NumberDXA and bioimpedance do not agree, and they disagree most during active weight change. Why a lean mass percentage is partly a property of the instrument.